pomalidomide has been researched along with Benign Neoplasms in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Ding, X; Elvassore, N; Jiang, B; Kong, Y; Liu, H; Liu, L; Mi, Q; Qiu, X; Ren, C; Shao, Y; Yang, X; Yin, Q; Zhao, Q | 1 |
| Che, J; Chen, D; Dong, X; Li, J; Luo, X; Mi, T; Rao, Z; Tian, T; Wang, H; Wu, Y; Xu, Y; Zhou, Y; Zhou, Z; Zhu, CL | 1 |
| An, J; Chen, D; Chen, L; Gu, Z; He, B; Lin, S; Yan, W; Zeng, Z | 1 |
| Schmidt, C | 1 |
| Edil, BH; Fujiwara, Y; He, J; Schulick, RD; Sun, Y; Torphy, RJ; Yanaga, K; Zhu, Y | 1 |
| Agarwal, S; Eddins, MJ; Kodrasov, MP; Kumar, S; LaRocque, JP; Marblestone, JG; Mattern, MR; Nicholson, B; Sterner, DE; Wu, J | 1 |
| Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S | 1 |
| de Rezende, LC; Guimarães, MC; Rangel, LB; Silva, IV | 1 |
| Bodera, P; Stankiewicz, W | 1 |
| Lentzsch, S; Pan, B | 1 |
| Bokar, J; Cooney, MM; Dowlati, A; Dreicer, R; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Rodal, MB | 1 |
| Clarke, IA; Dalgleish, AG; Dredge, K; Marriott, JB; Muller, G; Stirling, D | 1 |
| Chandula, RS; Chen, RS; Chen, Y; Muller, GW; Stirling, DI; Teo, SK; Thomas, SD | 1 |
| Bartlett, JB; Dalgleish, AG; Dredge, K | 1 |
| Corral, LG; Fleming, YW; Stein, B; Zhu, D | 1 |
5 review(s) available for pomalidomide and Benign Neoplasms
| Article | Year |
|---|---|
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Topics: Animals; Catalytic Domain; Drug Design; Drug Screening Assays, Antitumor; Fluorescence Resonance Energy Transfer; Humans; Lenalidomide; Ligands; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Thalidomide; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitin-Specific Proteases | 2014 |
Regulatory T cell as a target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; Lenalidomide; Mice; Models, Animal; Myeloablative Agonists; Neoplasms; T-Lymphocytes, Regulatory; Thalidomide; Vidarabine | 2010 |
Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Evaluation, Preclinical; Humans; Immunomodulation; Lenalidomide; Neoplasms; Patents as Topic; Thalidomide | 2011 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
3 trial(s) available for pomalidomide and Benign Neoplasms
| Article | Year |
|---|---|
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferative Disorders; Neoplasms; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide; Treatment Outcome | 2014 |
Phase I trial of pomalidomide given for patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunologic Factors; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Thalidomide; Treatment Outcome; Young Adult | 2012 |
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Humans; Inflammation; Lenalidomide; Lipopolysaccharides; Lymphocyte Activation; Male; Middle Aged; Neoplasms; Phosphodiesterase Inhibitors; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type II; Signal Transduction; Solubility; Thalidomide; Tumor Necrosis Factor-alpha | 2002 |
7 other study(ies) available for pomalidomide and Benign Neoplasms
| Article | Year |
|---|---|
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Topics: Animals; Cell Proliferation; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Half-Life; Humans; K562 Cells; Lenalidomide; Ligands; Mice; Neoplasms; Protein Kinase Inhibitors; Proteolysis; Structure-Activity Relationship; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases | 2021 |
Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader.
Topics: Cell Line, Tumor; Drug Design; Humans; Neoplasms; Proteolysis; Proto-Oncogene Proteins c-akt | 2022 |
Serendipitous discovery of Class I HDAC inhibitors from rational design of molecular glue degraders targeting HDAC.
Topics: Histone Deacetylase Inhibitors; Humans; Neoplasms; Thalidomide | 2024 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cytotoxicity, Immunologic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunity; Immunologic Factors; Immunomodulation; Melanoma, Experimental; Mice; Neoplasms; T-Lymphocyte Subsets; Thalidomide | 2018 |
Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Humans; In Vitro Techniques; Neoplasms; Sodium Chloride; Stereoisomerism; Thalidomide | 2003 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Neoplasms; Prostatic Neoplasms; Thalidomide | 2008 |